Ingrid Digernes1, Endre Grøvik1, Line B. Nilsen1, Cathrine Saxhaug2, Oliver Geier1, Edmund Reitan2, Dag Ottar Sætre3, Birger Breivik4, Kari Dolven Jacobsen5, Åslaug Helland5, and Kyrre Eeg Emblem1
1Department of Diagnostic Physics, Oslo University Hospital, Oslo, Norway, 2Department of Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, Norway, 3Department of Radiology, Østfold Hospital Trust, Kalnes, Norway, 4Deptartment of Radiology, Hospital of Southern Norway, Kristiansand, Norway, 5Department of Oncology, Oslo University Hospital, Oslo, Norway
Synopsis
Stereotactic
radiosurgery of brain metastases can cause pseudoprogression. In this study, we
use Vessel Architectural Imaging, based on dual echo DSC, to investigate the
course of vascular function of brain metastases, both prior to and after
pseudoprogression have occurred. Our results show that pseudoprogressing metastases
were characterized by underperfused and oxygen-deprived tissue, and micro- and
macrovessel pruning in the peritumoral regions. This was in contrast to peritumoral
regions of responding metastases as well as normal-appearing brain tissue.
Introduction
Stereotactic radiosurgery (SRS) is an important
treatment option for patients with brain metastases. However, SRS can cause
pseudoprogression, a radiation-induced tissue damage which leads to a transient
increase with subsequently decrease of the lesion volume on post-gadolinium T1-weighted
images. The time from SRS to an apparent tumor volume increase, i.e.
pseudoprogression (TTP), and the time from pseudoprogression to subsequent
manifested regression (TTR) can vary from a few months and up to years1
(Figure 1). Studies of pseudoprogression using perfusion Magnetic Resonance
Imaging (MRI) to understand the mechanisms of pseudoprogression are mainly
limited to one follow-up exam or only after the occurrence of pseudoprogression.
Here, we use Vessel Architectural Imaging (VAI)2 to investigate the
course of vascular function of brain metastases, prior to and after
pseudoprogression have occurred.
Methods
Seventeen patients with 19 metastases from non-small
cell lung cancer or malignant melanoma received SRS (15-25 Gy) to the metastases
+ 2mm margin. MRI, including dual echo dynamic susceptibility contrast (DSC)
imaging, was acquired pre-SRS, every 3 months the first year and every 6 months
thereafter. Seven patients with 8 metastases were classified as
pseudoprogression based on follow-up or histology. DSC and VAI data enabled
measures of oxygenation status, as well as micro- and macrovascular blood
volume, blood flow and vessel calibers.3 Peritumoral region were
defined by a 4mm wide dilation around the enhancing lesion. Fractions of
deviant vascular characteristics in peritumoral region were calculated based on
the number of voxels with parameter values under/above the 20th/80th
percentile of the normal-appearing brain tissue. Longitudinal data from
pseudoprogressing metastases was normalized to pre-SRS, TTP and TTR.
Results
Median TTP was 6 months (range: 3 – 18 months) and subsequent median TTR occurred at 6
months (range: 3 - 17 months). The peritumoral
region of pseudoprogressing metastases were characterized by underperfused and
oxygen-deprived tissue, and micro- and macrovessel pruning, both prior to and
after SRS (p < 0.05, relative to normal-appearing brain) (Figure 2A-D). In
responding metastases, by contrast, no difference between peritumoral regions
and normal brain was found. Moreover, a trend towards increased fraction of oxygen-deprived
tissue and microvessel pruning were observed after the manifestation of
pseudoprogression on post-gadolinium T1-weighted images.Discussion and Conclusion
Our findings show that metastases developing
pseudoprogression are characterized by poor vascular function in the
peritumoral region compared to responding metastases and normal-appearing brain
tissue. The increase in fraction of oxygen-deprived tissue after the
manifestation of pseudoprogression are in line with histological findings
showing hypoxia-inducible factors in tissue with pseudoprogression.4
Combined, our data provide valuable and novel insight into the vascular
function in SRS-treated metastases developing pseudoprogression. Acknowledgements
No acknowledgement found.References
1. Parvez K et al. Int J Mol Sci.
2014;15:11832-11846.
2. Emblem KE et al. Nat
Med. 2013;19(9):1178-83
3.
Digernes I et al. J Cereb Blood Flow
Metab. 2017;37(6):2237-2248
4. Nonoguchi et al. J Neurooncol. 2011;105:423-431.